GDF11 dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
GDF11 is the protein behind the young blood story. Two famous mouse papers in 2013 and 2014 said it drops with age and that topping it up makes old animals young again. A human test built to measure it properly found it does not drop with age, and higher levels went with frailty.
Evidence grade for GDF11: Preliminary. The rule: studied in people, but no published study has had people take it. The sum on this page: 1 human study where nobody was given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 0
- Found nothing
- 0
Dose
No human dose established
No published study on this page has given this compound to people and reported a result.
1 human study where nobody was given it
3 effects reported, 2 unwanted, 1 wanted, by people using it, not a trial
Goal pages: Muscle and strength, Heart and circulation
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
GDF11 is the protein behind the young blood story. Mouse papers said it drops with age and that topping it up makes old animals young. Later work found the tests used could not tell it apart from myostatin. Nobody has ever given it to a person in a study.
What people take it for
- Turning back ageing, based on the young blood headlines.
- Heart and muscle health in older age.
What studies in people showed
Nobody has given GDF11 to a person in a published trial. The human work only measured it. A test that could tell it from myostatin found it does not drop with age. Myostatin dropped in men, and neither dropped in women. In older adults with a badly narrowed heart valve, higher GDF11 went with being frail and having diabetes. It also went with going back into hospital after valve surgery. That is the opposite of the youth story. In mice, the heart result failed when another team tried to repeat it. Some animal studies still find that extra GDF11 helps heart scarring and stroke.
What people report
Reports, not study results
The good
- We have not collected real user reports. Interest comes from the young blood headlines, not from anyone's results.
The bad
- Products sold as GDF11 cannot be judged. There is no known dose and no human data at all.
- In the one human measuring study, higher levels went with frailty, not youth.
Where these come from: The human numbers come from the one measuring study on this page. The notes on products and interest come from longevity forums and news coverage, as listed on this page.
My bottom line
The famous claim did not survive a better test. I would not inject a protein that nobody has given to a person, sold on a 2013 mouse paper.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
What people using it report
Real people telling you what happened to them. Nobody checked it, and the people who post are not a fair sample, so it cannot prove anything works. It is still the best guide on this page to what people actually do with GDF11, what they expect, and what goes wrong. The full account, including the negative reports, is below.
Animal and lab work, not yet tested in people
Real results, but from animals or cells, not people. What works in a mouse often does not work the same way in a person. Nobody can patent this, so nobody would ever earn back the cost of a study in people. That is usually why there is none. The record on this one is set out below.
- Keeping or building muscle1 animal or lab study
34 of the 36 indexed goals have no study of any kind behind GDF11
No study in people, animals or cells on this page reports a result for these. That does not prove GDF11 does nothing for them. It does mean anything you have heard about GDF11 and one of these did not come from a study cited here.
Show full evidence
What is GDF11?
GDF11 is the protein behind the young blood story. Two famous mouse papers in 2013 and 2014 said it drops with age and that topping it up makes old animals young again. A human test built to measure it properly found it does not drop with age, and higher levels went with frailty.
GDF11 is the protein behind the young blood story. In 2013, a paper in the journal Cell said it is a blood factor that falls with age. Putting it back reversed age-related heart enlargement in mice. In 2014, a Science paper said it reversed age-related muscle weakness in mice. Those two results started ten years of public interest, plus a lot of supplement and clinic marketing.
Then someone measured it properly. GDF11 and myostatin differ by only eleven building blocks in the part that does the work. So a test built to find one usually picks up the other too. One group built a test that tells them apart and ran it on people. The picture flipped. Myostatin, not GDF11, falls with age in men. Neither falls in women. And people with higher GDF11 were more likely to be frail and to have diabetes.
This page reports the argument without settling it, because it is not settled. What it will not do is repeat the 2013 headline as if the last ten years did not happen.
How does GDF11 work?
GDF11 uses the same receptor and the same signal inside the cell as myostatin. In heart muscle it sends that signal more strongly than myostatin does. The shared receptor and near-identical working part are not a side note. They are the direct cause of the fight over measuring it, because lab tests struggle to tell the two apart.
What have studies in people found about GDF11?
One measuring study and no trials. Nobody has ever given GDF11 to a person in a published trial. The human evidence is about what GDF11 levels do and what they go along with, and it points away from the famous claim.
- With a test able to tell GDF11 from myostatin, GDF11 did not fall with age. Myostatin fell in men, and neither fell in women.
- In older adults with a badly narrowed heart valve, higher GDF11 went with frailty, diabetes and past heart problems.
- After valve replacement surgery, people who started with higher GDF11 were more likely to go back into hospital and to have several bad outcomes.
- No person has been given GDF11 in a published trial, for any reason.
What this does not tell you: The human data only watch what happens. They come largely from one group and one set of heart surgery patients, who are a specific and unwell group. They show GDF11 does not behave the way the 2013 story needs. They do not show GDF11 is harmful, and they cannot. Two things going together in sick people does not mean one causes the other.
What do people who took GDF11 report?
This is what real people say happened to them, good and bad. Nobody measured it. A report cannot tell a real effect from the lift people get just from expecting it to work, from a diet or training change made at the same time, or from what was really in the vial. We still put it near the top. It is the next best thing to a study in people: what happens when real people use it, including what goes wrong.
- Interest comes almost entirely from the young blood story and media coverage of experiments joining the blood of young and old mice, not from any human result.
- Products sold as GDF11 exist and cannot be judged. There is no approved product, no known dose, and no data of any kind from people taking it to compare against.
Sources: Longevity forums and consumer coverage. Included to explain where the demand comes from, not as evidence of anything.
The state of the research
GDF11 is the clearest warning in ageing science about lab tests that cannot tell two proteins apart. It is worth learning as a general lesson, not just a fact about one molecule. GDF11 and myostatin differ by eleven building blocks in the part that does the work. If your test cannot tell them apart, a drop in one can really be a drop in the other. A result about making old animals young can turn out to be about the wrong protein.
That is not a what-if here. The rebuttal paper says plainly that the tests used in the original work did not pick up GDF11 alone. The group that built a test that could found the age pattern running the other way in people.
Where the field really stands is more interesting than either side's headline. Giving extra GDF11 does seem to help in several animal disease models, including heart scarring and stroke. So the molecule may well do something useful. What has not survived is the claim that made it famous: that GDF11 falls with age and topping it back up makes you young. Anything sold to you on that idea is being sold on a 2013 paper and ten years of contradiction.
The evidence, in charts
Fig. 1a · how many people
1study in people cited, but none says how many people took part
number of people not stated
We do not draw a total, because none of the studies in people on this page gives one. Read the sources below for what each study measured.
We read the number of people from the source lines on this page. Where a line gives no number, we count nothing for it. We do not guess.
Fig. 1b · evidence mix
1 of 6 sources here is a study in people. The rest are not.
- Study in people · done in people117%
- Animal study · done in animals467%
- Review of studies · sums up other studies117%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 5 different years, 2013 to 2023, counted from the list of sources on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Biologic
- Molecule weight
- Precursor 407 amino acids, 45,091 Da. Mature signalling domain is residues 299 to 407, 109 amino acids, the same length as myostatin's (UniProt O95390).
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
Half-life as stated on file: Circulates as a latent complex. No verified circulating half-life is asserted here.
No amino acid sequence is on file for GDF11, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2016Quantification of GDF11 and myostatin in human aging and cardiovascular disease
The make-you-young story about this protein fails once you use a test that can tell it apart from its lookalike. Researchers built a test that separates GDF11 from myostatin. Myostatin, not GDF11, falls with age in healthy men. Neither falls in healthy women. In older adults with a badly narrowed heart valve, higher GDF11 went with being frail and having diabetes. It also predicted going back into hospital after valve surgery. Nobody was given anything here.
The most important citation on this page. A mass spectrometry assay that resolves GDF11 from myostatin on unique sequence features. Myostatin, not GDF11, declines with age in healthy men; neither declines in healthy women. In older adults with severe aortic stenosis, those with higher GDF11 were more likely to be frail and to have diabetes, and higher baseline GDF11 predicted rehospitalisation and adverse events after valve replacement.
- Review of studies2023GDF11 and aging biology: controversies resolved and pending
A 2023 review of the whole argument. It says many studies have since found that giving extra GDF11 helps in animal models of heart scarring, stroke and metabolism problems. It also lists the questions still open. Read it as where an unfinished argument stands, not a verdict.
The most recent even-handed account. It states that many studies have since confirmed exogenous GDF11 can improve physiology in disease models including cardiac fibrosis, experimental stroke and disordered metabolism, while reviewing the controversies that remain open. Read it as the current state of an unfinished argument, not a verdict.
- Animal study2013Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy
In mice. The original claim: GDF11 falls with age, and putting it back reversed age-related heart enlargement in old mice joined to young ones. The whole young blood story rests on this paper.
Mouse, heterochronic parabiosis. The original claim: GDF11 declines with age and restoring it reversed age-related cardiac hypertrophy. This is the paper the young blood narrative rests on.
- Animal study2014Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle
In mice. The muscle half of the original claim, that restoring GDF11 reversed age-related muscle problems.
Mouse. The muscle half of the original claim.
- Animal study2015GDF11 increases with age and inhibits skeletal muscle regeneration
In mice and rats, with some human blood. A drug company team could not repeat the earlier results. They say the tests used could not pick out GDF11 alone. On their own test, GDF11 tended to go up with age in old rat and human blood, and it slowed muscle repair in mice. That is the opposite of the original claim.
The central rebuttal, from a Novartis-led group, and note the title. They report the earlier claims were not reproducible, that the reagents used to detect GDF11 were not GDF11-specific, that GDF11 trends upward with age in aged rat and human sera on a specific assay, and that GDF11 inhibited muscle regeneration in mice. Their conclusion is that GDF11 might be a target for blockade in sarcopenia, which is the opposite of the original therapeutic direction.
- Animal study2015GDF11 does not rescue aging-related pathological hypertrophy
In mice. Another team tried to repeat the heart result, and it failed.
Mouse. A direct failure to replicate the cardiac result.
Common questions
Has GDF11 been tested in people?
Not in a completed trial cited here. 1 human study where nobody was given it. GDF11 is the protein behind the young blood story. Two famous mouse papers in 2013 and 2014 said it drops with age and that topping it up makes old animals young again. A human test built to measure it properly found it does not drop with age, and higher levels went with frailty.
What is the GDF11 dosage?
No human dose established. No published study on this page has given this compound to people and reported a result. 1 human study where nobody was given it
Is GDF11 FDA-approved?
Not an approved drug. No study has ever given GDF11 to people.
Does GDF11 decline with age?
On the best human measurement, no. A test built to tell GDF11 from myostatin found GDF11 did not fall with age. Myostatin fell in men, and neither fell in women. The original claim that it falls came from tests that the rebuttal paper says did not pick up GDF11 alone.
So was the young blood result wrong?
The specific role given to GDF11 did not hold up, and the heart result failed when others tried to repeat it. That is not the same as saying nothing happens in young blood experiments. It means GDF11 was probably not the reason, and that the original tests could not tell it from a close cousin.
Is GDF11 good or bad, then?
Nobody knows yet, and the honest answer has two halves. In people, higher GDF11 went with frailty and worse results after heart surgery. In animal disease models, giving GDF11 has helped heart scarring, stroke and metabolism in several studies. Both can be true. Nobody has tested it in a person.
Can I buy it?
Products exist and there is no way to judge them. There is no approved GDF11 product, no known human dose, and no published data of any kind from people taking it.